



(12) UK Patent (19) GB (11) 2 150 567 (13) B

(54) Title of invention

Process for production of 1, 2, 4-triazolones

(51) INT CL⁴; C07C 125/065 C07D 249/12

(21) Application No
8430275

(22) Date of filing
30 Nov 1984

(30) Priority data

(31) 556727

(32) 30 Nov 1983

(33) United States of America (US)

(43) Application published
3 Jul 1985

(45) Patent published
13 Jan 1988

(73) Proprietor
Bristol-Myers Company

(Incorporated in USA—New
York),

345 Park Avenue
New York
NY 10154
United States of America

(72) Inventor
Gary D. Madding

(74) Agent and/or
Address for Service
Langner Parry,
52—54 High Holborn
London WC1V 6RR


(52) Domestic classification (Edition J)
C2C 1450 215 220 227 22Y 250
252 25Y 29X 29Y 305 30Y 322 327
32Y 351 352 364 366 368 36Y 388
401 402 40Y 620 624 625 650 662
761 768 AA AB LY TW
U1S 1347 C2C

(56) Documents cited
None


(58) Field of search
C2C

PROCESS FOR PRODUCTION OF 1,2,4-TRIAZOLONES

This invention describes an improved, more economical process for the synthesis of a valuable chemical intermediate (I)




used in the manufacture of the antidepressant agent 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-(2-phenoxyethyl)-2H-5 1,2,4-triazol-3(4H)-one which is also known as nefazodone.




This subject intermediate, 5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazolone, of Formula I is also known as MJ 14814 and its current synthesis, disclosed in pending application U.S. patent application serial No. 06/509,266 as Example 5, is shown in Scheme 1. An overall yield of 33% for Scheme 1 is predicted from yield calculations of the individual steps in Example 5 of the pending application.

Scheme 1



As can be seen in Scheme 1, the preparation of MJ 14814 starts with phenol and ethyl acrylate, an obnoxious material with a high vapor pressure. This process has been successfully scaled up and used repeatedly giving MJ 14814 in 25-30% overall yield from 5 phenol.

MJ 14814 is converted to the antidepressant agent nefazodone (MJ 13754) as disclosed in the above cited pending application. This conversion involves reaction of MJ 14814 with 1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine hydrochloride (10)



10 Preparation of MJ 14814 via Scheme 1 involves six steps and four isolated intermediates, two of which are liquids requiring purification by vacuum distillation.

15 By contrast, the improved process described hereinafter is comprised of four steps involving only three isolated intermediates, all of which are solids, with an overall yield of MJ 14814 of 40-55% from phenol. In comparison, the prior art method, represented by Scheme I, is a longer process requiring more labor and providing MJ 14814 in much lower yield.

20 The following references relate to component steps of the instant process described herein.


1. Dow Technical Bulletin, "Developmental 2-Ethyl-2-Oxazoline XAS-1454 Ethyloxazoline: An Intermediate for Aminoethylation." This reference describes the synthesis of N-(2-phenoxyethyl)propionamide, an intermediate compound of the instant process.

2. W. Reid and A. Czack, Ann. 676, pp. 121-129 (1964).

This reference teaches the reaction of imidoyl ethers with ethyl carbazate to give amidrazone which then cyclize on further heating to 1,2,4-triazoles as outlined below in Scheme 2.

5


Scheme 2



However, there is no disclosure of the use of N-substituted imidoyl ethers which would be necessary to obtain a desired N-substituted triazolone.

3. M. Pesson, et al., Bull. Soc. Chim., Fr., pp. 1367-71
10 (1962). This reference reports a very low yield synthesis (0.3%) of a triazolone with the desired substitution pattern via the process shown below in Scheme 3.


Scheme 3



The authors state that imidoyl ethers of secondary amides are difficult to make (p. 1364, bottom second column). Pesson, et al., do disclose preparation of a triazolone with the desired substitution pattern but via a synthesis, shown as Scheme 4, which is different from that in

the instant process. The reference synthesis begins with an imidoyl ether of a primary amide to give an intermediate carbethoxy hydrazone which is then reacted with a primary amine.

Scheme 4



5 Note that the carbazole displaces the imine function in Scheme 4 representing another feature distinguishing the process of the instant invention.


Pesson, et al., also disclose that thioamides are more reactive than amides, giving N-substituted amidrazone on reaction 10 with carbazole. However, when the N-substituent is alkyl, as required in the instant process, no reaction with ethyl carbazole was observed. Finally, Pesson, et al., teach activation of a thiobenzamide with dimethylsulfate followed by reaction with carbazole to give the triazolone product. Again, there is no disclosure involving activation 15 of alkyl carboxylic acid thioamides, a structural prerequisite for the instant process.

In summary, references 2 and 3 essentially describe reactions of certain amide derivatives with carbazole esters to eventually yield triazolone products but with distinguishing variations in 20 structural relationship to the product produced by the instant process.

This invention relates to an improved synthetic process which can be adapted for large-scale preparation of the useful chemical intermediate, 5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazolone. The instant process starts from phenol and 2-ethyl-2-oxazoline, raw materials which are cheap and readily available. The subject improved process offers advantages in economies of both material and labor costs by virtue of being shorter in length, involving fewer intermediate isolations, and providing a higher yield of product.

10 In one aspect, the invention provides a process for preparing 5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (I)

15




(I)

which comprises the consecutive steps of:

20 a) reacting phenol with 2-ethyl-2-oxazoline (V)


25



(V)

30 to give N-(2-phenoxyethyl)propionamide (IV)


35



7a -

b) activating the amide functional group of compound IV by reacting compound IV with an amide-activating agent so as to produce an imidoyl halide or ester intermediate of formula III;

05



III

10

said amide activating agent incorporating precursors of X and Y wherein Y is a halogen or alkoxy moiety and wherein X is an anion which results from the reaction between said amideactivating agent and compound IV,


15

(c) reacting the product of step b without isolating said compound III with a carbazate ester of formula H_2NNHCO_2R to give an alkyl [1-[(2-phenoxyethyl)amine]propylidene]-hydrazine carboxylate acid addition salt (II) corresponding to the anion of the amide-activating agent used in step b; and


20 (d) converting compound II into compound I by means of suitable thermal treatment of compound II in its free base form so as to form compound I.

25

The following flow chart, Scheme 5, illustrates the preparation of MJ 14814 from readily available starting materials utilizing one process in accordance with this aspect of the invention.



Scheme 5



In Scheme 5, R is C_{1-4} alkyl; X is Cl, Br, or SO_4 ; Y is Cl, Br, or OR; and amide activation is formation of a reactive imidoxy halide or ester by treatment of the amide with a suitable activating reagent such as $SOCl_2$, $SOBr_2$, $POCl_3$, dimethyl sulfate, phosgene, etc.

5 Step 1 of the scheme outlined above involves the reaction of phenol (1) and 2-ethyl-2-oxazoline (V) to give the intermediate compound N-(2-phenoxyethyl)propionamide (IV). The starting materials for step 1 are commercially available. Step 2, activation of the amide (IV), is accomplished by treatment of IV with an amide-activating reagent such as thionyl chloride, thionyl bromide, phosphorus oxychloride, phosgene, dimethyl sulfate, and the like, to give an imidoxy halide or ester intermediate (III). The preferred agents are phosgene or phosphorus oxychloride. Intermediate III need not be isolated but can be allowed to react with an alkyl carbazate of formula H_2NNHCO_2R ,

10 15 R = methyl is preferred, in step 3 .

In step 4 the hydrazinecarboxylate acid addition salt (II) is converted to its base form and cyclized to the desired triazolone product (1) by refluxing in a suitable inert organic solvent.

20 This four-step improved process involves isolation of only two intermediate products (IV and II) in addition to the target compound, I. By way of comparison, the current process involves six steps and the isolation of four intermediates, two of which are liquid and require purification by vacuum distillation. The reduced handling of intermediates in the instant process significantly reduces labor

25 costs in manufacture.

The synthesis of MJ 14814 as represented in the improved process is preferably carried out as a series of four steps going

- } O -

from the simplest starting materials (phenol, 2-ethyloxazoline) to MJ 14814. The steps comprising the process are as follows:

(1) Adding 2-ethyl-2-oxazoline to hot (150°) phenol and maintaining heating at about 175° for 16 additional hours. The oil 5 is then quenched in water to give N-(2-phenoxyethyl)propionamide (IV) in approximately 90% yield.


(2) Adding phosgene or phosphorus oxychloride to a solution of IV containing a catalytic amount of imidazole in methylene chloride to give a solution of the intermediate imidoyl chloride hydrochloride (III). 10

(3) Treating the solution of III with a solution of an alkyl carbazate to give alkyl [1-[(2-phenoxyethyl)amino]propylidene]-hydrazine carboxylate hydrochloride (II) is about 75% yield.

(4) The free base form of II, resulting from the treatment of II with a basifying agent, is heated in solution for several hours 15 to yield I in about 75%.

In another aspect the invention provides the acid addition salt:

20



(II)

25

wherein


R is lower (C_1-C_4) alkyl, and

30 X is an anion, or the free base form thereof.

- 11 -

Description Of Specific Embodiments

The process of this invention is illustrated in greater detail by the following examples directed to preferred embodiments of 05 the hereinafter described process steps. These examples, however, should not be construed as limiting the scope of the present invention in any way. In examples which follow, used to illustrate the foregoing processes, temperatures are expressed, as in the foregoing, in degrees centigrade (°). Melting points are uncorrected. The nuclear 10 magnetic resonance (NMR) spectral characteristics refer to chemical shifts (δ) expressed as parts per million (ppm) versus tetramethylsilane (TMS) as reference standard. The relative area reported for



the various shifts in the H NMR spectral data corresponds to the number of hydrogen atoms of a particular functional type in the molecule. The nature of the shifts as to multiplicity is reported as broad singlet (bs), singlet (s), doublet (d), triplet (t), quartet (q), 5 or multiplet (m). Abbreviations employed are DMSO-d₆ (deutero-dimethylsulfoxide), CDCl₃ (deuterochloroform), and are otherwise conventional. The infrared (IR) spectral descriptions include only absorption wave numbers (cm⁻¹) having functional group identification value. The IR determinations were employed using potassium bromide 10 (KBr) as diluent. The elemental analyses are reported as percent by weight.

EXAMPLE 1

Methyl Carbazate

An alternate name for this commercially available chemical 15 is methyl hydrazinocarboxylate. Methyl carbazate may also be synthesized by adding 85% hydrazine hydrate (58.5 g. 1.00 mole) with stirring to dimethyl carbonate (90.0 g. 1.00 mole) over a 10 min period. The mixture quickly warmed to 64° and became clear. The solution was stirred for another 15 min and the volatile materials were stripped 20 in vacuo at 70°. Upon cooling, the residue solidified. It was collected on a filter and after drying in air gave 69.3 g (76.9%) of white solid, m.p. 69.5-71.5°.

EXAMPLE 2

N-(2-Phenoxyethyl)propionamide (IV)

25 Phenol (13.1 moles) was heated to 150° and stirred under N₂ as 2-ethyl-2-oxazoline (12.2 moles) was added over 1 hr. The mixture was heated to 175 ± 3°. After heating 16 hr the oil was cooled to

about 140°, and then it was poured into water (12 L) with vigorous stirring. The mixture was stirred and cooled, and at about 25° the mixture was seeded with crystalline amide product. The material solidified and the supernatant was decanted. The residual solid was 5 stirred with 17 L of hot (85°) water. The mixture was cooled to 25°, seeded with the amide product, and the mixture refrigerated. The resulting granular solid was collected on a filter, rinsed with several portions of water and left to air dry. This gave a 92% yield of material, m.p. 61.5-64°.

10

EXAMPLE 3

A. Methyl [1-[(2-Phenoxyethyl]amino]propylidene Hydrazinecarboxylate Hydrochloride (II)

Phosgene (57.4 g, 0.58 mole) was added to a solution of N-(2-phenoxyethyl)propionsamide (IV, 112.0 g, 0.58 mole) and imidazole 15 (0.4 g, 0.006 mole) in 450 mL methylene chloride over 1 hr employing cooling so that the temperature did not exceed 25°. The reaction solution was then stirred at 25° for an additional 2.5 hr. A solution of methyl carbazate (52.5 g, 0.58 mole) in 500 mL methylene chloride was stirred over 25 g of a molecular sieve for 15 min and then the 20 solution was filtered. The filtrate was added under N₂ over a 0.5 hr period to the amide/phosgene solution while employing cooling 15-20°. A voluminous precipitate formed and the mixture was left to stir at 25° under N₂. After stirring for a total of 16 hrs, the mixture was filtered to isolate a solid. The solid was stirred in 750 mL methylene 25 chloride for 15 min, refiltered, and then dried in vacuo at 65° for 2 hrs to give 135 g (77%) white solid, m.p. 150-154°. Recrystallization of the product from isopropanol gives analytically pure material, m.p. 157-159°.

Anal. Calcd. for $C_{13}H_{19}N_3O_3 \cdot HCl$: C, 51.74; H, 6.68; N, 13.92; Cl, 11.75. Found: C, 51.73; H, 6.76; N, 13.94; Cl, 11.78.

NMR (DMSO-d₆): 1.15 (3,t [7.5 Hz]); 1.28 (3,t [7.5 Hz]); 2.74 (2,m); 3.66 (3,s); 3.70 (3,s); 3.81 (2,m); 4.19 (2,m); 6.98 (3,m); 5 7.31 (2,m); 9.67 (3,dt [6.8 Hz]); 10.04 (3,bs); 10.40 (3,bs); 10.90 (3,bs); 11.72 (3,bs).

IR (KBr): 695, 755, 1250, 1270, 1500, 1585, 1600, 1670, 1745, and 2900 cm^{-1} .

By appropriate modification of the above procedure (A),
10 thionyl chloride, thionyl bromide, dimethyl sulfate or other amide-activating agents may be employed in place of phosgene. A slightly different procedure (B) may also be used.

B. Methyl [1-[(2-Phenoxyethyl)amino]propylidene
Hydrazinecarboxylate (II Base Form)

15 Phosphorus oxychloride (53.0 g, 0.346 mole) was slowly added to a solution of N-(2-phenoxyethyl)propionamide (IV, 100.0 g, 0.518 mole) in 200 mL methylene chloride while being stirred under nitrogen. This solution was stirred for 4 hrs at which time a solution (dried over molecular sieve 4A) of methyl carbazate (46.4 g, 0.518 mole) in 600 mL
20 methylene chloride was added to the stirring solution over a 0.5 hr period. The resulting mixture was stirred and heated at gentle reflux under nitrogen for 18 hr. The mixture was then stirred with 1.0 L ice-water. The layers were separated and the aqueous layers extracted with an additional 200 mL methylene chloride. The aqueous layer was
25 made basic (pH 12) with aqueous sodium hydroxide. This resulted in precipitation of the free base form of II which was collected by filtration, rinsed with water and dried in air to give 65.8 g of product, m.p. 97-99°.

Anal. Calcd. for $C_{13}H_{19}N_3O_3$: C, 58.85; H, 7.22; N, 15.84.

Found: C, 59.02; H, 7.24; N, 15.92.

When this free base form of II is employed for the conversion to I, the preliminary basification step outlined in Example 4 (which 5 follows) is skipped. The base form of II is cyclized directly by gently refluxing in xylene according to the procedure of Example 4.

EXAMPLE 4

5-Ethyl-4-(2-phenoxyethyl)- 2H-1,2,4-triazol-3(4H)-one (I)

10 Methyl [1-[(2-phenoxyethyl)amino]propylidene]hydrazine carboxylate hydrochloride (II, 655.3 g, 2.17 mole) was stirred vigorously with 4.0 L methylene chloride, 2.4 L water and 179.4 g 50% NaOH (2.24 moles). The layers were separated and the organic layer was dried (K_2CO_3) and concentrated in vacuo. The residue was stirred 15 in 1.2 L xylene at gentle reflux for 2.5 hrs and then the solution was refrigerated. The solid was collected on a filter, rinsed with toluene and left to air dry. The white crystalline solid weighed 89.5 g (76.9%), m.p. 134.5-138°.


Additional purification may be accomplished in the following 20 manner. A portion of I (171.2 g, 0.73 mole) was dissolved in a boiling solution of 41.0 g (0.73 mole) KOH in 3.0 L water. The solution was treated with Celite (Registered Trade Mark) filter-aid and activated charcoal and filtered. The filtrate was stirred in an ice bath, and 37% HCl (61.0 mL, 0.73 mole) was added. The solid was collected on a filter, 25 rinsed with water and air dried to give 166.0 g (97% recovery) of fine white crystalline product, m.p. 137.5-138°.

Reference is made to the co-pending divisional application No. 87/02275 which is directed to the intermediates of Formula III

and to processes for their preparation.


CLAIMS :

1. A process for preparing 5-ethyl-4-(2-phenoxyethyl)-2H-1,2,4-triazol-3(4H)-one (I)



which comprises the consecutive steps of:


a) reacting phenol with 2-ethyl-2-oxazoline (V)



(V)

5

to give N-(2-phenoxyethyl)propionamide (IV)




(IV)

b) activating the amide functional group of compound IV by reacting compound IV with an amide-activating agent

so as to produce an imidoyl halide or ester intermediate of formula III;

05



III

10

said amide activating agent incorporating precursors of X and Y wherein Y is a halogen or alkoxy moiety and wherein X is an anion which results from the reaction between said amideactivating agent and compound IV,

15

(c) reacting the product of step b without isolating said compound III with a carbazate ester of formula H_2NNHCO_2R to give an alkyl [1-[(2-phenoxyethyl)amine]propylidene]-hydrazine carboxylate acid addition salt (II) corresponding to the anion of the amide-activating agent used in step b; and


(d) converting compound II into compound I by means of suitable thermal treatment of compound II in its free base form so as to form compound I.

25

2. The process of claim 1 wherein the amide-activating agent in step b is thionyl chloride, thionyl bromide, or dimethyl sulphate, phosphorous oxychloride, or phosgene.

30 3. The process of claim 1 or claim 2 wherein the thermal treatment of step d comprises refluxing the free base of compound II in a suitable inert organic solvent.

4. The acid addition salt:



05

(II)

wherein

R is lower (C₁-C₄) alkyl, and

10

X is an anion, or the free base form thereof.

15 5.\ The compound of formula II which is an acid addition salt of methyl [1-[(2-phenoxyethyl) amino]propylidene]hydrazine carboxylate or the free base form thereof.

6.\ The compound of formula II which is methyl [1-[(2-phenoxyethyl)amino]-
20 propylidene]hydrazine carboxylate hydrochloride.


7.\ A process for preparing a compound of Formula 1 comprising a process as described herein in Examples 2, 3 and 4.

8.\ A compound of Formula 1 prepared by the process of
25 any one of claims 1, 2, 3 or 7.

9.\ A compound of Formula 1 prepared as described herein in Examples 2, 3 and 4.


10. A process for preparing the compound of Formula II comprising :

30 a) reacting phenol with 2-ethyl-2-oxazoline (V)



to give N-(2-phenoxyethyl)propionamide (IV)

05




(IV)

10

b) activating the amide functional group of compound IV by reacting compound IV with an amide-activating agent so as to produce an imidoyl halide or ester intermediate of formula III.

15

20




25

said amide-activating agent containing precursors of X and Y, wherein Y is a halogen or alkoxy moiety and wherein X is an anion which results from the reaction between said amide-activating agent and compound IV,

30

c) reacting the product of step b without isolating said compound III with a carbazate ester of formula H_2NNHCO_2R to give an alkyl [1-[(2-phenoxyethyl)amine]propylidene]-hydrazine carboxylate acid addition salt (II)



(II)

wherein

R is lower ($\text{C}_1\text{-C}_4$) alkyl, and

X is an anion, corresponding to the anion of the amide-activating agent used in step b.

11. A process according to claim 10 which results in :

(1) methyl (1-(2-phenoxyethyl)amino)propylidene) hydrazine carboxylate or an acid addition salt thereof or

(2) methyl (1-(2-phenoxyethyl)amino)propylidene) hydrazine carboxylate hydrochloride.

12. A process for preparing a compound of Formula II comprising a process described in Example 3.

15 13. A compound of Formula II prepared by the process of Claim 10, 11, or 12.

2150567

Publication No.
2150567 A dated 3 July 1985

Patent Granted:

WITH EFFECT FROM
SECRET 13 JAN 1988

Application No.
8430275 filed on 30 November 1984

Priority claimed:
30 November 1983 in United States of America doc: 556727

Title:
Process for production of 1, 2, 4-triazolones

Applicant:
Bristol-Myers Company (USA-New York), 345 Park Avenue, New York, NY 10154,
United States of America.

Inventor:
Gary D Madding, 710 South Weinbach Avenue, Evansville, Indiana 47714,
United States of America.

Classified to:
C2C U1S

Examination requested 12 DEC 85

Address for Service:
Langner Parry, 52-54 High Holborn, London, WC1V 6RR.



Page 1

Last page

Printed by the Patent Office at St. Mary Cray, 01 MAY 85

2150567